Type : | Industriel |
Statut : | Ouvert |
Phase : | I |
Étape du traitement : | Traitements combinés |
Date d'ouverture : | 03/05/2018 |
Date clôture : | 06/08/2024 |
Promoteur : | Boehringer Ingelheim |
Progression du cancer: | Loco-régional |
This study has 2 parts. The first part was open to adults with advanced non-small cell lung cancer. The second part was open also to adults with other types of advanced cancer of the lung, brain, skin, and liver. After early encouraging results, more people with liver cancer can now take part in the study. The participants get a combination of two medicines called BI 836880 and ezabenlimab.
BI 836880 is a type of an antibody that blocks new blood vessel formation. New blood vessels are needed by the tumour to continue growing. Ezabenlimab is an antibody that may help the immune system fight cancer (immune checkpoint inhibitor).
The purpose of the first part of the study was to find out the highest dose of the BI 836880 that the participants can tolerate in combination with BI 754091. After the best dose of BI 836880 for the combination with ezabenlimab was found, it is used in the second part of the study. The purpose of the second part is to see whether the combination of BI 836880 and BI 754091 is able to make tumours shrink.
The participants are in the study as long as they benefit from and can tolerate treatment. During this time, they get infusions of BI 836880 and ezabenlimab every 3 weeks. The doctors also regularly check the general health of the participants.
- Cancers de la peau
- Mélanome
- Cancers basocellulaires
- Autres cancers de la peau
- Cancers digestifs
- Foie –Voie biliaire
- Cancers du système nerveux central
- Gliomes
- Cancers thoraciques respiratoires
- Cancer bronchique non à petites cellules
- Tumeur maligne du foie et des voies biliaires intrahépatiques - Cim10 : C22
- Tumeur maligne des bronches et du poumon - Cim10 : C34
- Carcinome in situ de la peau - Cim10 : D04
- Tumeur maligne du cerveau, sauf lobes et ventricules - Cim10 : C710